SCHEMBL2307259

SCHEMBL2307259

O=C1NCCN1c1ccc(S(=O)(=O)Nc2ccc3c(c2)CCC3)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
ALDH1A1 P00352 3/20 0.58
THRB P10828 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
POLB P06746 1/20 0.53
PKM P14618 3/20 0.53
HTR6 P50406 4/20 0.51
BRD1 O95696 2/20 0.50
BRPF1 P55201 2/20 0.50
DRD2 P14416 3/20 0.48
DRD3 P35462 3/20 0.48
HTR2A P28223 2/20 0.48
HTR2C P28335 2/20 0.48
CYP2D6 P10635 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C19 P33261 1/20 0.48
MLNR O43193 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2298556 0.82 ITGA1 (0.47) LMNASMN1; SMN2ALDH1A1PKMHTR6
SCHEMBL2302292 0.81 PKM (0.67) LMNASMN1; SMN2ALDH1A1POLBPKM
SCHEMBL2303199 0.81 LMNA (0.53) LMNASMN1; SMN2ALDH1A1THRBPOLB
SCHEMBL2300518 0.80 MAPT (0.61) LMNASMN1; SMN2ALDH1A1POLBPKM
SCHEMBL14239653 0.79 MAPT (0.47) LMNASMN1; SMN2ALDH1A1L3MBTL1POLB
SCHEMBL2302229 0.79 HTR6 (0.47) LMNASMN1; SMN2ALDH1A1POLBPKM
SCHEMBL2305062 0.79 CES1 (0.58) ALDH1A1HTR6HTTGAA
SCHEMBL2301965 0.79 ALDH1A1 (0.60) LMNAALDH1A1PKMALOX12GAA
SCHEMBL2301221 0.79 IDO1 (0.50) LMNASMN1; SMN2ALDH1A1POLBPKM
SCHEMBL2299887 0.79 HTR6 (0.56) LMNAALDH1A1PKMHTR6HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
EP-2536693-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS Université Laval (CA) 2012-12-26 EP disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS CCNY, RPS4Y1, TPX2 LMNA 2765/4885SMN1; SMN2 2479/4885ALDH1A1 1937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.